KCNJ4
potassium inwardly rectifying channel subfamily J member 4, the group of Potassium inwardly rectifying channel subfamily J
Basic information
Region (hg38): 22:38426327-38455199
Links
Phenotypes
GenCC
Source:
No genCC data.
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the KCNJ4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | |||||
| missense | 12 | 12 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| inframe indel | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| splice region | 0 | |||||
| non coding | 1 | |||||
| Total | 0 | 0 | 12 | 0 | 2 |
Variants in KCNJ4
This is a list of pathogenic ClinVar variants found in the KCNJ4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
| Position | Type | Phenotype | Significance | ClinVar |
|---|---|---|---|---|
| 22-38426693-C-T | Benign (Apr 16, 2019) | |||
| 22-38426901-G-A | not specified | Uncertain significance (Sep 07, 2022) | ||
| 22-38426909-C-G | not specified | Uncertain significance (Aug 08, 2022) | ||
| 22-38426946-G-A | not specified | Uncertain significance (Jun 11, 2021) | ||
| 22-38426949-G-A | not specified | Uncertain significance (Feb 06, 2023) | ||
| 22-38426962-C-T | not specified | Uncertain significance (Mar 17, 2023) | ||
| 22-38427093-C-T | not specified | Uncertain significance (May 26, 2024) | ||
| 22-38427131-T-C | Benign (Apr 16, 2019) | |||
| 22-38427164-G-C | not specified | Uncertain significance (Jun 09, 2022) | ||
| 22-38427268-T-A | Uncertain significance (Sep 10, 2021) | |||
| 22-38427421-C-T | not specified | Uncertain significance (Oct 06, 2022) | ||
| 22-38427547-G-A | Malignant tumor of prostate | Uncertain significance (-) | ||
| 22-38427550-C-A | not specified | Uncertain significance (Jan 17, 2024) | ||
| 22-38427808-C-T | not specified | Uncertain significance (Mar 05, 2024) | ||
| 22-38427823-C-T | not specified | Uncertain significance (Jul 13, 2022) | ||
| 22-38427846-G-A | not specified | Uncertain significance (Dec 04, 2023) |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| KCNJ4 | protein_coding | protein_coding | ENST00000303592 | 1 | 28874 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.965 | 0.0350 | 0 | 0 | 0 | 0 | 0.00 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 3.97 | 128 | 331 | 0.386 | 0.0000246 | 2912 |
| Missense in Polyphen | 25 | 143.42 | 0.17431 | 1230 | ||
| Synonymous | 0.309 | 151 | 156 | 0.969 | 0.0000133 | 924 |
| Loss of Function | 2.99 | 0 | 10.4 | 0.00 | 4.50e-7 | 120 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00 | 0.00 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.00 | 0.00 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium (By similarity). {ECO:0000250}.;
- Pathway
- Oxytocin signaling pathway - Homo sapiens (human);Cholinergic synapse - Homo sapiens (human);Antiarrhythmic Pathway, Pharmacodynamics;Disopyramide Action Pathway;Procainamide (Antiarrhythmic) Action Pathway;Phenytoin (Antiarrhythmic) Action Pathway;Fosphenytoin (Antiarrhythmic) Action Pathway;Bopindolol Action Pathway;Timolol Action Pathway;Carteolol Action Pathway;Bevantolol Action Pathway;Practolol Action Pathway;Dobutamine Action Pathway;Isoprenaline Action Pathway;Arbutamine Action Pathway;Amiodarone Action Pathway;Levobunolol Action Pathway;Metipranolol Action Pathway;Mexiletine Action Pathway;Lidocaine (Antiarrhythmic) Action Pathway;Quinidine Action Pathway;Sotalol Action Pathway;Epinephrine Action Pathway;Betaxolol Action Pathway;Atenolol Action Pathway;Alprenolol Action Pathway;Acebutolol Action Pathway;Muscle/Heart Contraction;Diltiazem Action Pathway;Propranolol Action Pathway;Pindolol Action Pathway;Penbutolol Action Pathway;Oxprenolol Action Pathway;Metoprolol Action Pathway;Esmolol Action Pathway;Bisoprolol Action Pathway;Bupranolol Action Pathway;Nebivolol Action Pathway;Amlodipine Action Pathway;Verapamil Action Pathway;Nitrendipine Action Pathway;Nisoldipine Action Pathway;Nimodipine Action Pathway;Ibutilide Action Pathway;Tocainide Action Pathway;Flecainide Action Pathway;Isradipine Action Pathway;Nifedipine Action Pathway;Felodipine Action Pathway;Nadolol Action Pathway;Carvedilol Action Pathway;Labetalol Action Pathway;Neuronal System;Phase 4 - resting membrane potential;Cardiac conduction;Muscle contraction;Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits;Activation of GABAB receptors;GABA B receptor activation;GABA receptor activation;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;Activation of G protein gated Potassium channels;Classical Kir channels;G protein gated Potassium channels;Inwardly rectifying K+ channels;Potassium Channels
(Consensus)
Intolerance Scores
- loftool
- rvis_EVS
- -0.89
- rvis_percentile_EVS
- 10.3
Haploinsufficiency Scores
- pHI
- 0.209
- hipred
- Y
- hipred_score
- 0.855
- ghis
- 0.662
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.806
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Low | Medium |
| Primary Immunodeficiency | Medium | Low | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Kcnj4
- Phenotype
Gene ontology
- Biological process
- potassium ion transport;regulation of ion transmembrane transport;potassium ion import across plasma membrane
- Cellular component
- plasma membrane;voltage-gated potassium channel complex;basolateral plasma membrane;cell junction;cytoplasmic vesicle membrane;postsynaptic membrane
- Molecular function
- inward rectifier potassium channel activity;protein binding;G-protein activated inward rectifier potassium channel activity;PDZ domain binding